Evidence map›Paper›PMID 38892246›Full record

ArticleInternational journal of molecular sciences2024

Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.

Emmanuel Chamorey, Marc Pujalte-Martin, Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, Guilhem Roubaud, Philippe Beuzeboc, Remy Largillier, Delphine Borchiellini, Claude Linassier and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emmanuel ChamoreyEpidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.ORCID 0000-0002-6841-4571
Marc Pujalte-MartinMedical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.ORCID 0000-0002-4636-768X
Jean-Marc FerreroMedical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
Hakim MahammediMedical Oncology Department, Centre Jean Perrin, 63000 Clermond Ferrand, France.
Gwenaelle GravisMedical Oncology Department, Institut Paoli Calmette, 13009 Marseille, France.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France.
Philippe BeuzebocMedical Oncology Department, Institut Curie, 75005 Paris, France.
Remy LargillierMedical Oncology Department, Centre Azuréen de Cancérologie, 06250 Mougins, France.
Delphine BorchielliniMedical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
Claude LinassierMedical Oncology Department, Centre Hospitalier Régional Universitaire, 37000 Tours, France.
Hélène BougesOncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.
Marie-Christine Etienne-GrimaldiOncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.ORCID 0000-0002-0758-311X
Renaud SchiappaEpidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.ORCID 0000-0001-5104-9507
Jocelyn GalEpidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.ORCID 0000-0002-1802-118X
Gérard MilanoOncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (

Indexed as

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAntineoplastic AgentsFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisAbiraterone AcetateAntineoplastic Agentsabiraterone acetatepharmacodynamicspharmacogeneticsprostate cancer

Identifiers

PMID38892246
PMCPMC11172583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.